All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke to Erik Thiele Orberg, Technical University of Munich, Munich, DE. We asked, How can we use microbial-derived metabolites to prevent GvHD?
How can we use microbial-derived metabolites to prevent GvHD?
Microbial-derived metabolites are small, easily synthesized molecules that may offer the same benefits as fecal microbiota transplant, without concerns for transmitting infectious diseases, like COVID-19. Orberg envisions that metabolites could be administered prophylactically to patients undergoing stem cell transplantation.
Editorial Theme | Novel therapies for the treatment of GvHD
Currently, there are only two approved treatments for GvHD: ruxolitinib, indicated for steroid resistant (SR) aGvHD, and ibrutinib, used in patients with cGvHD who have failed one or more...
COVID-19 vaccination for hematopoietic stem cell transplant patients
The SARS-CoV-2 pandemic has changed the world over the last year and impacted almost every part of our lives. In particular, patients with hematologic malignancies have been...
Subscribe to get the best content related to GvHD delivered to your inbox